L-β-dioxolane uridine analogs and their pharmaceutical compositions
AssigneesYale University, University of Georgia Research Foundation, Inc.
InventorsChung K. Chu, Yung-Chi Cheng, Fucheng Qu
Life of this patent
Estimating the term…
Abstract
The present invention relates to the discovery that certain β-L-dioxolane nucleoside analogs which contain a uracil base, and preferably, a 5-halosubstituted uracil base, exhibit unexpectedly high activity against Epstein-Barr virus (EBV), Varciella-Zoster virus (VZV) and Herpes Virus 8 (HV-8). In particular, the compounds according to the present invention show potent inhibition of the replication of the virus (viral growth) in combination with very low toxicity to the host cells (i.e., animal or human tissue). Compounds are useful for treating EBV, VZV and HV-8 infections in humans.
Claims5
A β-L nucleoside compound according to the structure:
- where R is Br, Cl or CF3.
A pharmaceutical composition comprising a therapeutically effective amount of (2S,4S)-1-[(hydroxymethyl)-1,3-dioxanyl-4-yl]-5-chloroaracil or (2S,4S)-1-[(hydroxymethyl)-1,3-dioxanyl-4-yl]-5-bromouracil in combination with a pharmaceutically acceptable additive, excipient or carrier.
A pharmaceutical composition comprising a therapeutically effective amount of a compound according to the structure:
- where R is Br, Cl or CF3 in combination with a pharmaceutically acceptable additive, excipient or carrier.
Dependencies are inferred from the claim text.